KRN7000 applied to diabetes research

Alcohol Facilitates CD1d Loading, Subsequent Activation of NKT Cells, and Reduces the Incidence of Diabetes in NOD Mice

Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets

Alpha-GalCer C20:2 May be a More Efficacious Candidate Drug Than alpha-GalCer C26:0 (KRN7000) for iNKT Cell Mediated Protection from Type 1 Diabetes

Innovative immune-based therapeutic approaches for the treatment of type 1 diabetes mellitus

Role of regulatory invariant CD1d-restricted natural killer T-cells in protection against type 1 diabetes

Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in prevention of autoimmune diabetes in non-obese diabetic mice treated with alpha-galactosylceramide

Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes

Subcongenic analysis of genetic basis for impaired development of invariant NKT cells in NOD mice

Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes

CD1d-restricted NKT regulatory cells: functional genomic analyses provide new insights into the mechanisms of protection against Type 1 diabetes

NKT cell defects in NOD mice suggest therapeutic opportunities

NKT cells and type-1 diabetes and the "hygiene hypothesis" to explain the rising incidence rates

The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice

Ligand-dependent induction of noninflammatory dendritic cells by anergic invariant NKT cells minimizes autoimmune inflammation

Lipid antigen presentation in the immune system: lessons learned from CD1d knockout mice

Reversal of established autoimmune diabetes by H60-loaded immature dendritic cells plus the natural killer T cells ligand alpha-Galactosylceramide

Valpha14 NK T cell-triggered IFN-gamma production by Gr-1+CD11b+ cells mediates early graft loss of syngeneic transplanted islets

Loss of IL-4 secretion from human type 1a diabetic pancreatic draining lymph node NKT cells

Involvement of sulfatide in beta cells and type 1 and type 2 diabetes

Interleukin-4 but not interleukin-10 protects against spontaneous and recurrent type 1 diabetes by activated CD1d-restricted invariant natural killer T-cells

Regulatory natural killer T cells protect against spontaneous and recurrent type 1 diabetes

Failure of alpha-galactosylceramide to prevent diabetes in virus-inducible models of type 1 diabetes in the rat

In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers

Back to top

 

New 7DW8-5 glycolipid

7DW8-5

Now available 7DW8-5 glycolipid derivative of Alpha-GalCer for human and mice iNKT immunoresearch

 

Meet Funakoshi Company
at the following meetings:

AACR
Washington DC
April 1-5, 2017

The 11th Annual Meeting of Japanese Society for Epigentics
Tokyo, Japan
May 22-23, 2017

The 36th Annual Meeting of Japanese Association of Forensic Toxicology

The 21st Annual Meeting of Japanese Assocation of Cancer Immunology
Chiba, Japan
June 28-30, 2017

The Japanese Society for Genome Editing
Osaka, Japan
June 28-30, 2017

The 76th Annual Meeting of the Japanese Cancer Association
Yokohama, Japan
September 28-30, 2017

NIH Festival
Bethesda, Maryland
September 2017

ASCB
Philadelphia, PA
December 2-6, 2017